Not So Different: A Podcast from The Center for Biosimilars

S6 Ep24: Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition

Listen

Description

Happy Birthday Adalimumab Biosimilars: Reflecting on the First Year of US Competition


EMA Approves First Ustekinumab Biosimilar, Uzpruvo


Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars


IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe


IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition


Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings


Biosimilar SB5 Matches Originator in Safety, Efficacy for Inflammatory Diseases After Switching


Postapproval Pharmacovigilance Review Confirms Comparable Safety Between Sandoz Biosimilars, Originators